Giovanni Escobar assumes the role of Chief Operating Officer at Innocoll

Princeton, New Jersey – May 30, 2023 – Innocoll Pharmaceuticals Ltd. (“IPL”), a global biotech pharmaceutical company and portfolio business of Gurnet Point Capital (“GPC”), announced the appointment of Giovanni Escobar, a seasoned Quality and Operations executive, as Chief Operating Officer. As part of this appointment, Giovanni will also serve as Chief Operating Officer of IPL’s two subsidiaries: Syntacoll GmbH (“Syntacoll”), a contract development and manufacturing organization (“CDMO”) specializing in collagen-based technology platforms, and Innocoll Biotherapeutics (“Innocoll”), a global biotech company focusing on delivering non-opioid alternatives for postsurgical pain management. 

Giovanni Escobar joined Innocoll as the Chief Operating Officer (COO), bringing with him a wealth of experience and expertise in the biopharmaceutical, pharmaceutical, and medical device Industry. Giovanni will spearhead operational strategies and lead the Innocoll and Syntacoll operational business into its next phase of growth. With a proven track record of success and a deep understanding of the intricacies of the biopharmaceutical landscape, Giovanni is poised to make a transformative impact. 

“We are delighted to welcome Giovanni to the Innocoll as our new Chief Operating Officer,” said Kimball Hall, President and CEO of Innocoll. “His extensive leadership experience, strategic acumen, and commitment to advancing healthcare aligns perfectly with our mission. With Giovanni on board, we are confident in our ability to accelerate the development and delivery of innovative biotherapeutic solutions to patients in need.” 

Giovanni comes to Innocoll with over 30 years of experience in the biologics, medical device, and pharmaceutical industry. Prior to this appointment, Giovanni held key leadership positions at several prominent companies, with his last being SVP and Site Head at Abzena, a private equity held CDMO. Prior to Abzena, Giovanni held multiple leadership positions at GlaxoSmithKline within Supply Chain, Quality, and Operations such as Site Head, Contract Manufacturing Program Head, Site Q Head, Contract Manufacturing Quality Head, and Global Category Quality Head. His proven ability to navigate complex challenges and optimize production processes will be instrumental in advancing Innocoll’s mission to bring life-changing biotherapies to market. 

Giovanni said, “I am honored to join the outstanding team at Innocoll and Syntacoll as the Chief Operating Officer. The company’s dedication to advancing healthcare through breakthrough biotherapies and improving patient outcomes is truly inspiring. I look forward to collaborating with the talented individuals at Innocoll, Syntacoll and the GPC team while contributing to further improve, develop, and commercialize transformative collagen platform and opioid free postsurgical pain biotherapeutic solutions.” 

Giovanni holds a Masters in Pharmaceutical Manufacturing from Steven’s and has a history of driving growth, fostering innovation, and fostering a collaborative culture within organizations. His unique perspective and leadership style are expected to complement Innocoll’s existing strengths and position the company for continued success. 

About Innocoll Pharmaceuticals Limited
Innocoll Pharmaceuticals Limited is a global biotech pharmaceutical company headquartered in Athlone, Ire-land and is a subsidiary of Innocoll Biotherapeutics Holding Limited. The Innocoll group of companies is focused on the development and commercialization of pharmaceutical technologies to meet some of today’s most im-portant healthcare challenges. Innocoll is a portfolio business of Gurnet Point Capital. 

About Gurnet Point Capital
Gurnet Point Capital is a leading healthcare fund that invests in de-risked life sciences companies. Gurnet Point primarily focuses on businesses that have high growth potential in the late product development and commercialization stages of their evolution. These companies become partners not just because of their capacity to generate economic value, but also because of their potential to deliver social impact. Gurnet Point’s team of highly experienced industry executives work closely with its portfolio companies, with an active approach driving operational transformation and outsized returns.